Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Pharmaceuticals	38.04M	44.43M	38.93M	12.82M	12.34M
Pharmaceuticals Growth	-14.40%	14.13%	203.68%	3.90%	19.22%
Total	38.04M	44.43M	38.93M	12.82M	12.34M
Total Growth	-14.40%	14.13%	203.68%	3.90%	19.22%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Taiwan	38.04M	44.43M	38.93M	12.82M	12.34M
Taiwan Growth	-14.40%	14.13%	203.68%	3.90%	19.22%
Total	38.04M	44.43M	38.93M	12.82M	12.34M
Total Growth	-14.40%	14.13%	203.68%	3.90%	19.22%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 6, 2026

Data Sources Report a data error